OncoMatch/Clinical Trials/NCT07006727
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Official title: A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Is NCT07006727 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies multiple treatments including 225Ac-ETN029 and 111In-ETN029 for small cell lung carcinoma.
Treatment: 225Ac-ETN029 · 111In-ETN029 — The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Radioligand therapy
Other
Cancer type
Small Cell Lung Cancer
Neuroendocrine Tumor
Non-Small Cell Lung Carcinoma
Prostate Cancer
Pancreatic Cancer
Cervical Cancer
Tumor Agnostic
Thyroid Gland Carcinoma
Biomarker criteria
Required: DLL3 expression (testing required; no eligibility threshold specified)
Demographics
Prior therapy
Must have received: systemic therapy
disease progression following, or intolerance to, at least 1 line of systemic therapy, including platinum-containing chemotherapy
Cannot have received: DLL3-targeted therapy
Exception: SCLC (prior DLL3-targeted therapy allowed)
Any prior DLL3-targeted therapy (except for SCLC)
Cannot have received: radioligand therapy
Exception: NEPC patients in expansion
Any prior RLT (except for NEPC patients in expansion)
Lab requirements
Blood counts
ANC < 1.0 x 10^9/L, hemoglobin < 9 g/dL, or platelet count < 75 x 10^9/L [excluded]
Kidney function
eGFR < 60 mL/min/1.73m2 calculated using the CKD-EPI 2021 formula or measured [excluded]
Cardiac function
QTcF ≥ 470 msec [excluded]
ANC < 1.0 x 10^9/L, hemoglobin < 9 g/dL, or platelet count < 75 x 10^9/L; QTcF ≥ 470 msec; eGFR < 60 mL/min/1.73m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Of Iowa · Iowa City, Iowa
- Massachusetts General Hospital · Boston, Massachusetts
- Corewell Health William Beaum Hosp · Royal Oak, Michigan
- Fred Hutchinson Cancer Research Center · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07006727 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior DLL3-targeted therapy, radioligand therapy disqualifies patients from enrollment.
Does this trial require DLL3?
Yes, DLL3 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify